Sanara MedTech stock: Q3 revenue rises, outlook is cut

Published on 11/13/2026 at 00:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sanara MedTech stock posted third-quarter revenue growth, but lowered its full-year 2026 sales outlook. Merger costs weighed on earnings.

Quarterly growth meets lower guidance

Sanara MedTech reported stronger third-quarter revenue, while operating income and continuing operations earnings weakened.
The company reduced its full-year 2026 revenue outlook as merger-related costs continued to weigh on expenses.
The proposed MiMedx transaction remains subject to regulatory review after shareholder approval.

SMTI, US79957L1008, Illustration mit AI erstellt.

Sanara MedTech reported third-quarter results on Thursday, November 12, 2026, with revenue growth offset by higher expenses and a lower full-year outlook. The company said net revenue rose 8 percent year over year to 28.4 million US dollars for the quarter ended September 30, according to the StockTitan report carrying the GlobeNewswire release.

Revenue growth loses earnings momentum

Gross profit increased 8 percent to 26.3 million US dollars, while the gross margin held at 93 percent. Operating income fell to 0.7 million US dollars from 2.9 million US dollars a year earlier.

Sanara posted a 1.3 million US dollar loss from continuing operations, or 0.15 US dollars per diluted share, compared with income of 0.8 million US dollars, or 0.09 US dollars per diluted share, in the prior-year quarter. Adjusted EBITDA, a non-GAAP measure, rose to 5.6 million US dollars from 4.9 million US dollars.

Soft tissue products drive sales

Soft tissue repair revenue increased 10 percent, supported by CellerateRX Surgical and BIASURGE. Bone fusion revenue declined 5 percent, partly offsetting the gain in soft tissue products.

Operating expenses climbed 19 percent to 25.6 million US dollars. The quarter included approximately 3.0 million US dollars in legal and advisory services tied to strategic initiatives and the pending merger with MiMedx Group.

Lower outlook raises execution stakes

Sanara lowered its 2026 net revenue guidance to 110 million to 115 million US dollars from the previous range of 116 million to 121 million US dollars. For the first nine months, revenue reached 84.4 million US dollars, up 12 percent from the comparable period.

The proposed MiMedx transaction received shareholder approval in September, but the companies continue to work through regulatory review. The combination therefore remains an important event for investors alongside the company's operating performance.

Sanara MedTech's surgical focus

Sanara MedTech is based in Fort Worth, Texas, and develops, markets and distributes surgical and wound-care products in the United States. Its portfolio includes CellerateRX, BIASURGE, FORTIFY TRG and FORTIFY FLOWABLE products for physicians, hospitals, clinics and post-acute care facilities. The company focuses on specialized medical technology and biologic solutions for surgical tissue repair and wound care.